Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Novartis to Conduct Clinical Trial for Flu Vaccine in Japan
September 21, 2009
- Eli Lilly Japan to Achieve Sales of US$1 Bil. This Year
September 21, 2009
- NEW PRODUCTS
September 21, 2009
- ESC Congress in Barcelona
September 21, 2009
- R&D NEWS IN BRIEF
September 21, 2009
- NDA Review Time Shortened in 2008 but Still Far from Target
September 21, 2009
- Korosho Eliminates Redundancies from All-Patient Surveys and EPPV
September 21, 2009
- REGULATORY NEWS IN BRIEF
September 21, 2009
- Bristol-Myers Renews Website
September 21, 2009
- da Vinci Surgical System, V.A.C. ATS Treatment System Recommended for Approval
September 21, 2009
- FDG-PET Test for Pediatric Tumors Recommended for Approval as Advanced Healthcare Service
September 21, 2009
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
September 21, 2009
- Korosho's Proposal Regarding Vaccination against New-Type Flu Acceptable
September 21, 2009
- GSK Enters Urology Market with Avolve
September 21, 2009
- Healthcare Providers to Be Preferentially Vaccinated against New-Type Flu
September 21, 2009
- Novartis Prepares Trial for New-Type Flu Vaccine with Adjuvant
September 14, 2009
- Ono Licenses Asimadoline from Tioga
September 14, 2009
- R&D NEWS IN BRIEF
September 14, 2009
- MEDICAL DEVICE NEWS IN BRIEF
September 14, 2009
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
September 14, 2009
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…